MedPath

Alverine

Generic Name
Alverine
Drug Type
Small Molecule
Chemical Formula
C20H27N
CAS Number
150-59-4
Unique Ingredient Identifier
46TIR1560O
Background

Alverine is a smooth muscle relaxant used to relieve cramps or spasms of the stomach and intestines. It is therefore useful in treating irritable bowel syndrome (IBS) and similar conditions. It can also be used to help relieve period pain.

Indication

Used to relieve cramps or spasms of the stomach and intestines. It is also useful in treating irritable bowel syndrome (IBS) and similar conditions. It can also be used to help relieve period pain. Alverine citrate is also under investigation to increase the cytotoxic effects of the proteasome inhibitor MG132 on breast cancer cells.

Associated Conditions
Abdominal Pain
Clinical Trials
Related News

The Safety and Efficacy of Alverine in the Treatment of Cirrhotic Portal Hypertension

Phase 2
Not yet recruiting
Conditions
Hypertension, Portal
Interventions
First Posted Date
2024-06-25
Last Posted Date
2024-06-25
Lead Sponsor
Shanghai Changzheng Hospital
Target Recruit Count
30
Registration Number
NCT06473493

The Efficacy and Safety of Alverine in the Treatment of Portal Hypertension in Patients With Liver Cirrhosis

Phase 2
Not yet recruiting
Conditions
Hypertension, Portal
Interventions
First Posted Date
2024-06-24
Last Posted Date
2024-06-24
Lead Sponsor
Shanghai Changzheng Hospital
Target Recruit Count
178
Registration Number
NCT06470386

The Instant Efficacy and Safety of Alverine in Decreasing Portal Hypertension: an Exploratory Pilot Study

Phase 2
Conditions
Portal Hypertension
Interventions
First Posted Date
2022-08-19
Last Posted Date
2025-02-25
Lead Sponsor
Shanghai Changzheng Hospital
Target Recruit Count
20
Registration Number
NCT05508633
Locations
🇨🇳

Shanghai Changzheng hospital, Shanghai, Shanghai, China

Effectiveness of On-demand Meteospasmyl® Use in Irritable Bowel Syndrome (IBS)

Phase 4
Completed
Conditions
Irritable Bowel Syndrome
Interventions
Drug: anti spasmodic agents
First Posted Date
2011-07-28
Last Posted Date
2014-11-04
Lead Sponsor
Laboratoires Mayoly Spindler
Target Recruit Count
436
Registration Number
NCT01404923

Efficacy and Safety of Meteospasmyl® in Irritable Bowel Syndrome

Phase 4
Completed
Conditions
Irritable Bowel Syndrome
Interventions
Drug: placebo
First Posted Date
2007-10-11
Last Posted Date
2008-10-01
Lead Sponsor
Laboratoires Mayoly Spindler
Target Recruit Count
400
Registration Number
NCT00542295
© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy